{"id":"NCT02073448","sponsor":"Galderma R&D","briefTitle":"Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.","officialTitle":"A Multicenter, Randomized, Double-blinded, Active-controlled Parallel Group Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2014-10","completion":"2014-10","firstPosted":"2014-02-27","resultsPosted":"2016-11-03","lastUpdate":"2017-03-28"},"enrollment":417,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"GK530G","otherNames":["Fixed-dose combination gel of Adapalene and Benzoyl Peroxide"]},{"type":"DRUG","name":"CD0271","otherNames":["Adapalene 0.1% Gel"]},{"type":"DRUG","name":"CD1579","otherNames":["Benzoyl Peroxide 2.5% Gel"]}],"arms":[{"label":"GK530G","type":"EXPERIMENTAL"},{"label":"CD0271","type":"ACTIVE_COMPARATOR"},{"label":"CD1579","type":"ACTIVE_COMPARATOR"}],"summary":"This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the treatment of acne vulgaris for up to 12 weeks, in the Japanese patients.","primaryOutcome":{"measure":"Percent Changes From Baseline in Total Lesion Counts","timeFrame":"Baseline - Week12","effectByArm":[{"arm":"CD0271","deltaMin":68.6,"sd":null},{"arm":"GK530G","deltaMin":82.7,"sd":null},{"arm":"CD1579","deltaMin":81.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":13,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":101},"commonTop":["Nasopharyngitis","Skin irritation","Eczema","Dysmenorrhoea","Skin papilloma"]}}